nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2009 | Editorial

What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

verfasst von: Paolo Zanotti-Fregonara, Elif Hindié, Marie Elisabeth Toubert, Domenico Rubello

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Excerpt

The introduction into clinical practice of recombinant human thyroid-stimulating hormone (rhTSH) has marked a turning point in the management of patients with differentiated thyroid cancer. RhTSH offers a safe and reliable alternative to thyroid hormone withdrawal by avoiding both the clinical consequences of hypothyroidism, with a positive impact on quality of life and work productivity, and the potential risk of cancer growth due to a long-lasting endogenous TSH stimulation. …

Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61–74. doi:10.1111/j.1365-2265.2004.02060.x.CrossRef

Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid 2008;18:687–94. doi:10.1089/thy.2008.0162.PubMedCrossRef

Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063–8. doi:10.1210/jc.2001-011918.PubMedCrossRef

Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926–32. doi:10.1210/jc.2005-1651.PubMedCrossRef

Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371–7. doi:10.1007/s00259-003-1230-1.PubMedCrossRef

Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008;35:1457–63. doi:10.1007/s00259-008-0754-9.PubMedCrossRef

Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49–64. doi:10.1677/erc.1.00830.PubMedCrossRef

Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228–34. doi:10.1210/jc.84.9.3228.PubMedCrossRef

Zanotti-Fregonara P, Duron F, Keller I, Khoury A, Devaux JY, Hindié E. Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. Nucl Med Commun 2007;28:257–9. doi:10.1097/MNM.0b013e32804c58c2.PubMedCrossRef

10.

Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11:865–9. doi:10.1089/105072501316973127.PubMedCrossRef

11.

Zanotti-Fregonara P, Keller I, Rubello D, Calzada-Nocaudie M, Devaux JY, Hindié E. TSH variations may explain some positive 131I therapy scans in patients with negative diagnostic scans. J Endocrinol Invest. In press.

12.

Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888–96. doi:10.1056/NEJM199709253371304.PubMedCrossRef

13.

Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799–807. doi:10.1677/ERC-07-0120.PubMedCrossRef

14.

Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid 2004;14:465–7. doi:10.1089/105072504323150804.PubMedCrossRef

15.

Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. J Clin Endocrinol Metab 2004;89:585–90. doi:10.1210/jc.2003-031650.PubMedCrossRef

16.

Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 2006;65:519–23. doi:10.1111/j.1365-2265.2006.02626.x.CrossRef

17.

Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148–51. doi:10.1210/jc.86.11.5148.PubMedCrossRef

18.

Zanotti-Fregonara P, Hindié E, Faugeron I, Moretti JL, Ravasi L, Rubello D, et al. Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma. Minerva Endocrinol 2008;33:313–27.PubMed

19.

Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638–44. doi:10.1038/sj.bjc.6601319.PubMedCrossRef

20.

Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504–15. doi:10.1210/jc.2007-1154.PubMedCrossRef

Titel: What role for recombinant human TSH in the treatment of metastatic thyroid cancer?
verfasst von: Paolo Zanotti-Fregonara
Elif Hindié
Marie Elisabeth Toubert
Domenico Rubello
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-1046-0

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Lung ventilation-perfusion scintigraphy in children on long-term parenteral nutrition

Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma

Head and neck squamous cell carcinoma (HNSCC) – detection of synchronous primaries with 18F-FDG-PET/CT

Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification

Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen

Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy